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Physiologicallybasedpharmacokinetic (PBPK) modelingwas usedto -m thelow-doseexposure
ofpatients to the carcinogen2,4-toluenediamine (2,4-TDA) rdeased from the adation ofthe
polyesterurethane foam (PU) used in Meme silicone breastimplants. Thetissues arerepresnted
as five compartments: liver, Idney, gasrointestinal tract, slowly perfused tissues (e.g., fat), and
richlyperfusedtissues(e.g., muscle). The PBPKmodelw ttedto theplasma and urine concen-
trations of2,4-TDA and its metabolite 4-AAT (4-N-aetyl-2-amino toluene) in rats given low
doses of2,4-TDAintravenously andsubcutaeously. The rat modaldwasextrapolated to simulate
oral and implant routes in rats. After adjusting for human physiological parmeters, the model
was then used to predict the bioavailability of2,4-TDA released from a typical 4.87-gpolyester
uretane foam implant founddin apatientwhoweighed 58 kgwith the Meme andhad thebreast
implantfor 10years. Aquantitative riskassessament for2A-TDAwaspeinrnfedandthe polyester
urethane foam did present an unreasonable risk to health for the pt K work implant,
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Polyurethanes have been used in breast
implant covers, pacemaker leads, hemodialyz-
er potting material, and other medical appli-
cations. The degradation ofpolyurethanes in
vivohas long been a concern due to both the
release ofpotentiallyharmful materials aswell
as mechanical failure. The composition ofthe
polyurethane degradation products depends
on the original formulation of the polymer.
The polyester urethane (PU) foam cover of
the Meme breast implant (or Replicon;
Surgitek Corporation, Racine, WI) was made
from apolyester resin and a 80:20 mixture of
2,4-toluene diisocynate and 2,6-toluene
diisocyanate (2,4-TDI, 2,6-TDI) (1). One of
the degradation products of TDI is 2,4-
toluenediamine (2,4-TDA). Data in experi-
mental animals showed that the PU foam
cover degraded within 6-12 months of
implantation (2). This result was consistent
with the clinical observations in patients with
Meme breast implants (3,4). Our own in
vitro studies indicated that 2,4-TDA was
slowly released over time byhydrolytic degra-
dation when PU foam samples were incubat-
ed under mild physiological conditions (5,6).
The amount and rate of 2,4-TDA produc-
tion observed in vitro varied with the condi-
tions of PU foam exposure (7-9). The car-
cinogenicity of2,4-TDA was studied exten-
sively in mice, rats, and other species
(10-19). Exposure ofpatients to this rodent
carcinogen, one ofthe degradation products
ofMeme breast implants, is apotential health
risk (20-24).
Physiologically based pharmacokinetic
(PBPK) modeling uses physiological para-
meters such as organ volumes, blood flows,
and excretion flows, and chemical specific
parameters such as tissue solubility and bio-
transformation rates. This type ofmodeling
uses these physiological parameters to com-
plete a material balance on the component
of interest in the body. An important fea-
ture ofthis type ofmodel is predicting the
absorption, distribution, metabolism, and
elimination of the simulated chemical.
Animal data using one uptake route can be
extrapolated to another route and/or from
animal species to humans with minor
changes to the PBPK model. The extrap-
olative value of this approach in human
health risk assessment has long been used
for manydrugs and chemicals (25-28).
The objectives of this study were to
develop a PBPK model to simulate the fate
of low-dose exposure of 2,4-TDA from
implant degradation and assess the poten-
tial health risk in patients with Meme PU
foam-covered silicone breast implants. The
PBPK model was initially developed to fit
experimental data obtained in rats injected
intravenously (iv) and subcutaneously (sc)
with low doses of 2,4-TDA, 0.54 mg/kg
and 0.44 mg/kg, respectively (29). Once
the PBPK model adequately simulated the
fate of2,4-TDA and its metabolite by dif-
ferent routes of exposure, the model was
scaled up to a human PBPK model using
appropriate physiological and pharmacoki-
netic parameters. The model was solved
numerically using an adaptive grid Runge-
Kutta method in the Mathcad PLUS 6.0
software package (MathSoft, Cambridge
MA). Using sensitivity analysis, we evaluat-
ed the rat model and determined the rate-
limiting steps that changed with doses,
routes, and species. Statistical validation of
the fit ofthe experimental rat results to the
PBPK model simulation results was per-
formed as described by Krishman and
Anderson (25). The kinetic behavior of2,4-
TDA and its metabolite were derived from
the implant PBPK model for both rats and
humans. The simulated results were com-
pared to the available independent data for
validation (10-13,22,2,). Finally, a quanti-
tative risk assessment was performed to
assess the potential cancer risks in patients
with Meme silicone breast implants.
Methods
PBPKmodel The model consists offive tis-
sue compartments: two excreting compart-
ments [kidney and gastrointestinal (GI)
tract], slowly perfused tissues (e.g., fat), rich-
ly perfused tissues (e.g., muscle), and metab-
olizing tissue (liver). The model is very simi-
lar to styrene and methylene chloride PBPK
models (27,28). The hydrolytic PU foam
degradation rate constant, Kd, was zero order
with an experimentally determined value of
88 ng 2,4-TDA/g foam/day as previously
reported (5,6). The degradation of the PU
foam in vivo was assumed to produce only
one product, 2,4-TDA (29). The PBPK
model for 2,4-TDA accounts for hepatic
metabolism, which is known to produce an
active metabolite (18,19). Although there
were at least eight known metabolites of2,4-
TDA in the liver, 2,4-TDA was assumed
only to have one metabolite, 4-acetylamino-
2-aminotoluene (4-AAT), in this model for
simplicity (19,29). The rate of production
of 4-AAT was controlled by an adjustable
selectivity in the model (19). The selectivity
was defined as the fraction ofmetabolites of
2,4-TDA that were converted to 4-AAT.
The value ofthe selectivity was set according
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to the published fraction ofmetabolites that
were 4-AAT (0.32) (1,9. The metabolite 4-
AATwas also distributed, metabolized to an
unknown product, and excreted (11). 2,4-
TDAwas modeled to be an equilibrium sys-
tem between protein-bound and free 2,4-
TDA, with the ratio of bound to free kept
constant so that 9.7% ofthe 2,4-TDA was
free, as shown in the initial experimental rat
plasma samples (29). As shown in Figure 1,
blood of uniform composition exiting the
mix point flowed through the implant into
the arterial circuit. The uniformly mixed
arterial blood was then distributed to other
compartments in the body. The blood flow
rate to each compartment was determined
from published physiological measurements
(26). The distribution coefficient (D), which
related to the blood/tissue partition coeffi-
cient(Jf, was defined as the ratio ofthe con-
centration of2,4-TDA or metabolite in the
tissue to its emergent venous blood concen-
tration. The 2,4-TDA (and 4-AAT) distrib-
ution coefficients and metabolism rate con-
stants were obtained from previously pub-
lished radioactive distribution studies in rats
and mice (11-13). Venous blood exits each
compartment at equilibrium with the tissue
in that compartment. Unlike the arterial cir-
cuit, the blood exiting each compartment in
the venous circuit did not have a uniform
composition of2,4-TDA or its metabolite.
Before the blood was returned to the
implant and arterial circuit, itwas complete-
lymixed at the mix point.
All ofthe 2,4-TDA was metabolized in
the liver, and the metabolites were then
returned to the venous blood for circulation
to the other compartments for subsequent
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Figure 1. Flow diagram of the physiologically
based pharmacokinetic (PBPK) model.
Abbreviations: a,, jth blood flow rate (ml/hr), C,
2,4-toluenediamine (2,4-TDA) concentration
(mol/mI); a, arterial blood; g, gastrointestinal (GI)
tract; i, mixed blood, k, kidney; L, liver; r, richly
perfused tissues; s, slowly perfused tissues; v,
venous blood; 4-AAT, 4-N-acetyl-2-amino toluene.
absorption, further metabolism, or excre-
tion. Metabolites or 2,4-TDA can be
excreted in either the urine or the feces
(19). The complete model equations are
discussed in the Appendix. Table 1 lists the
range of the parameters used in the model
forboth rats and humans (26).
Experimental data. Three sets of inde-
pendent experimental data were used to
calibrate the model (29).
After iv injection with 0.52 mg/kg 2,4-
TDA, blood samples were collected from
five female CDF (F-344)/Crl rats atvarious
time intervals (0.05, 0.15, 0.25 hr, etc.) up
to 48 hr after dosing. Both the 2,4-TDA
and 4-AAT plasma results were measured
by a validated GC/MS analytical method
with a detection limit of0.1 ng/ml. These
results were used to fit the metabolism
parameters for both 2,4-TDA and 4-AAT
in the model. As discussed previously, dis-
tribution coefficients were assigned from
radioactive distribution studies (11,12,16).
Urine was obtained for analysis after
female CDF (F-344) CRL BR rats (n = 5)
received a single sc injection of 2,4-TDA
(0.44 mg/kg). The mean fraction of 2,4-
TDA excreted unchanged was 0.22%
(range 27-51 ng/ml). The corresponding
concentration of urinary 4-AAT recovered
was less than 1% (range 103-188 ng/ml)
within 48 hr after dosing. These results
were used to set the urine/feces excretion
distribution coefficients.
In another study, a 14C-labeled foam
was synthesized from 14C-TDI comparable
to the foam used in the manufacture of
Meme breast implants; this 14C-labeled
foam was implanted sc in young female rats
at a dose comparable to 80 mg/kg.
Radioactivity was evaluated in urine, feces,
and selected tissues at various intervals post
implantation (1, 4, 12, and 24 hr, and 7,
15, 21, 28, and 56 days). At 56 days, the
cumulative excretion ofradioactive materi-
al amounted to 2% (urinary 0.9% and
Table 1.Values ofthe parameters used inthe physiologically based pharmacokinetic (PBPK) model (26)
Rat Human
Compartment Compartment
Compartment Blood flow(ml/hr) volume (ml) Blood flow(mVlhr) volume (ml)
Slowly perfused tissue 55.2 19.1 26,520 13,562
Richly perfused tissue 2,640 144.9 123,200 40,672
Liver 912 8.8 71,760 1,419
Kidney 702 1.7 46,800 243
Gastrointestinal tract 696 6.0 43,680 948
Total cardiac output 5,005 - 312,000 -
Range of cardiac output 4,980-8,040 - 2.84 x 105
(published, resting)
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Figure 2. Fitted results ofthe plasma concentrations for a 0.52 mg/kg iv bolus injection. Abbreviations: 2,4-
TDA, 2,4-toluenediamine; 4-MT,4-N-acetyl-2-amino toluene; Calc, calculated; Exp, experimental.
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fecal 1.1%) of the implanted dose. The
presence of radioactive material in rat uri-
nary and fecal excreta at 56 days indicated
a slow and continued degradation of
implanted PU foam in vivo. These results
were used to verify our fitted excretion data
as discussed above and as an independent
check ofthe tissue distribution parameters.
Results
Calibration usingiv bolusandscadministra-
tion ofalowdoseof2,4-TDA in therat.The
fitted experimental plasmaconcentrations fol-
lowing iv injection ofa 0.52-mg/kg dose 2,4-
TDA are shown in Figure 2. 2,4-TDA plas-
ma levels decreased rapidly following iv
administration in rats. Although this dose
would be expected to produce a blood con-
centration of6,500 ng/mi in the rat, the max-
imum initial plasma concentration was 633
ng/ml, indicating that 2,4-TDA was rapidly
bound to plasma proteins confirming previ-
ous observations (22. The blood flow para-
meters; and compartment volumes were set
from published physiological parameters; the
tissue distribution coefficients were obtained
from published radioactive distribution stud-
iesasdiscussedearlier (11-13, 26). Evenwith
these constraints, the model was robust
enough to accurately correlate the experimen-
tal results using only the metabolism parame-
tersforboth 2,4-TDAand4-AAT.
From the material balance results, the
area under the serum concentration time
curve (AUC) of2,4-TDA from time zero to
infinity was determined to be 62.176
ng/hr/ml, the total body dearance (Cl) was
8,363 ml/hr, and the volume ofdistribution
(7Vd) was 1,379 ml/kg (30). Theelimination
halflife (tl2) offree 2,4-TDA in the plasma
was 0.074 hr due to its extensive binding to
plasma proteins (22). The protein bound
2,4-TDA is in equilibrium with the free 2,4-
TDA, which is biologically active. The
extent that protein binding influences the
delivery offree 2,4-TDA to the target organ
may change in certain human disease states
(30). After the first 6 hr, the plasmalevels of
2,4-TDA dropped to averylowvalue below
the analytical detection limits. As shown,
most ofthe administered dose of2,4-TDA
was rapidly metabolized, and very little was
excreted or absorbed (0.22%). The urinary
concentration of4-AAT reached nearly 500
ng/ml, well above detection limits, even
though less than 0.3% (weight) ofthe origi-
nal dose was excreted. Thus, the predicted
cumulative concentrations of4-AAT excret-
ed in the urine were well fitted to the urine
analysis data obtained from the rat subcuta-
neous study (29).
Kinetics of2,4-TDAfrom implantsimu-
lation in the rat. The simulated implant
results in the rat are shown in Figures 3 and
4. Unlike the intravenous cases, the implant
provided a continuous low-level dose of2,4-
TDA to the tissues. The predicted plasma
steady state concentration (C ) of2,4-TDA
was only 3.4 x 10-5 ng/ml. Therefore, we do
not recommend the use offree plasma 2,4-
TDA to monitor the breakdown of PU
foam. The plasma level of4-AAT was also
too low to be detected. Table 2 summarizes
the calculatedpharmacokinetic parameters of
free 2,4-TDA and 4-AAT following three
different routes ofadministration of a low
dose in the rat.
Kinetsof2,4-TDAfrom implantsimu-
lation in the human. The physiological and
biochemical parameters that were used to
adjust the rat model to a human model are
summarized in Tables 1 and 3. The tissue
distribution coefficients, which were
assumed to be the same for both rats and
humans, were obtained from the literature
(11-13). The metabolism parameter Vm.
was extrapolated by scaling on the basis of
(bodyweight)07, where45.27was thescaling
factor between rats and humans [scaling fac-
tor = (58/0.250)071 (27). The results ofthe
human PBPKsimulation areshown inTable
2. The model predicted that the C. offree
2,4-TDA and 4-AAT in plasma ofa patient
with 4.87 g Meme breast implants and body
weight of58 kgwould be 1.55 x 104 ng/ml
and 2.58 X 104 ng/ml, respectively (values
for the rat would be 3.40 x 10-5 ng/ml and
5.77 x 10-5 ng/ml, respectively). The lower
serum concentration values in the rat were a
direct result ofhigher metabolism because
Table2. Comparison of2,4-TDA iv bolus,feeding, and implantresults in ratand human models
Rat, 0.52 mg/kg Rat, 0.52 mg/kg Rat, 0.021 g Human, 4.872 g
iv bolus feeding implant implant
Percent original dose accumulated
Feces 0.053 0.052 0.047 0.019
Urine 0.224 0.220 0.239 0.309
Liver 7.5 x 10-5 0.017 0.514 1.75
Kidney 0.024 0.025 0.531 1.48
RPtissue 1.2 x 10-4 0.113 2.789 15.4
SPtissue 3.3x 10-4 0.043 0.701 9.55
GI tract 4.9x 10-4 0.099 1.973 6.06
Plasma clearance calculations
AUC (ng/hr/ml) 62.179 58.951 1.98x 10-4 0.846
2,4-TDAtl1 (hr) 0.074 0.776 Lifetime Lifetime
Clearance]ml/hr/kg) 8,360 8,820 9,320 2,175
Vd(ml/kg) 1,379 12,570 54,900 11,770
4-AATt1I2(hr) 0.389 0.863 Lifetime Lifetime
Abbreviations: iv, intravenous; AUC, area underthe curve, free 2,4-toluene diamine concentration in plasma vs. time; V.,
volume of distribution; 2,4-TDA, 2,4-toluenediamine; 4-AAT, 4-N-acety1-2-amino toluene; RP, richly perfused; SP, slowly
perfused; G6, gastrointestinal.
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Figure 3. Comparison of the plasma concentrations of 2,4-TDA following the intravenous bolus injection,
feeding, and implant in the rat. Abbreviations: 2,4-TDA, 2,4-toluenediamine; 4-AAT, 4-N-acetyl-2-amino
toluene.
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Table 3. Metabolism and excretion parameters
used inthe physiologically based pharmacokinetic
(PBPK) model
Metabolism and excretion
parameters
VmX(mol/hr)8
kmqmol/mI) V,m (mol/hr)@
km nXol/ml)
Urineflow(ml/hr)
2,4-TDADurine
4-AATD .
Fecesflow?milhr)
Blood volume (ml)
2,4-TDAdistributon coefficient
Slowlyperfusedtissue
Richlyperfusedtissue
Liver
Kidney
G6 tract
4-MTdistribution coefficient
Slowlyperfused tissue
Richlyperfusedtissue
Liver
Kidney
GItract
Ratvalue
0.12
7x10-7
0.01
3 x 10-7
0.75
0.5
10.0
0.60
20.0
1.0
1.0
5.0
3.0
5.0
1.0
0.4
1.0
10.0
10.0
Human
value
0.54
7x10-7
0.46
3x10-7
90
0.5
10.0
18
4,700
1.0
1.0
5.0
3.0
5.0
1.0
0.4
1.0
10.0
10.0
E
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Figure 4. Comparison of the plasma concentrations of 4-N-acety1-2-amino toluene (4-AAT) following the
intravenous bolus injection, feeding, and implant in the rat.
Abbreviations: VMiX, 2,4-TDA metabolism parameter
lmol/hr); Vrrnax, 4-AAT metabolism parameter (mol/hr); k,,
2,4-TDA metabolism parameter (mol/ml); kmm, 4-AAT
metabolism parameter (mol/mi); Dunne, distribution coeffi-
cientfor2,4-TDA or4-AATin urine (urne concentration/tis-
sue concentration.
"Scale-upfactorhuman/ratbased onbody mass(58kg/O.25kg)07(2?).
the distribution coefficients and relative
excretions were the same in these calcula-
tions. In the human, this corresponds to a
plasma level of 16 x 104 ng/ml oftotal 2,4-
TDA (free + conjugated; 9.7% free). Similar
to the rat implant we do not recommend
using free plasma 2,4-TDA to monitor the
breakdown of PU foam from breast
implants. However, urinary4-AAT maybe a
better biomarker (0.309% or 0.96 nglml).
Table 2 also shows alarge volume ofdistrib-
ution indicating high tissue uptake, low
clearance, and small AUC in the human
implant.
Kinetics of2,4-TDAfollowinglow-dose
ingestion in the rat. The model was also
used to predict the pharmacokinetics 2,4-
TDAintroduced byfeeding. For this simu-
lation, 0.52 mg/kg 2,4-TDA was delivered
to the GI tract and was slowly absorbed
into the blood by a first order rate constant
of 0.015 min-1. This rate absorbed about
99% of the 2,4-TDA in about 90 min
(16). Alongwith the results for the iv bolus
and the implant, the plasma 2,4-TDA and
4-AAT concentrations are shown in
Figures 3 and 4, respectively. At a given
low dose, the model predicted lower plas-
ma concentrations offree 2,4-TDA and 4-
AAT following the oral route compared to
iv bolus due to slower absorption rate.
However, these concentrations persisted for
a much longer period of time, so the area
under the plasma concentration time curve
was equivalent (AUC = 58.95 ng/hr/ml)
compared to exposure from the iv route.
The 4-AAT urinary concentration reached
a maximum of240 ng/ml after about 1 hr,
a very comparable level to the sc result
because the 2,4-TDA was introduced grad-
ually in both cases. The cumulative urinary
level of 4-AAT was determined to be less
than 0.3% (weight) ofthe original dose fol-
lowing an oral bolus dose of2,4-TDA.
Sensitivity analysis. The PBPK model
for 2,4-TDA, as shown in the Appendix, is
complex and has several adjustable parame-
ters that give it the flexibility to correlate a
large range of possible scenarios. Because
the blood volume, blood flow rate, tissue
volume, and excretion flow rates are set
from the physiological measurements, the
parameters such as distribution coefficients
and the metabolism rate constants, which
were obtained from published animal data
(11-13,16), were subsequently fitted to
experimental results. Such restraint limited
the model to reasonable predictions with
physiological implications.
The model predictions are sensitive to
many parameters. The model itself is based
on thephysiologyofthe system beingstudied
to keep it realistic. By using a sensitivity
analysis, the effect of a change in a parameter
on the model prediction can be identified
(25). With all models, large changes in some
parameters have almost no effect on the
model prediction. Also, small changes in
some parameters have drastic changes in
model predictions. Thus, asensitivityanalysis
can be used to identify parameters that are
critical to be measured byexperimental stud-
ies. The parameters that are notcritical to the
model prediction do not require the same
degree ofexperimental effort to quantify for
experimental validation ofthe model. The
usefulness ofthe PBPK approach is to use a
mathematical model to predict the results
that are difficult or impossible to obtain
experimentally (25). Thus, the point ofthe
PBPK model is not to predict results at all
points in the human or animal body and
comparetheresults toexperimental data atall
the points, but rather a few key results are
predicted, e.g., plasma concentrations and
excretion rates, and these are used for a sim-
plevalidation (25). Thephysiology is used to
predict the other unmeasurable points based
on the best available data (bloodflows, organ
volumes, etc.). This simple validation will
give substantially more predictive power than
simple one- or two-compartment pharmaco-
kinetic models, which are often validated
withthe same typeofverylimiteddata.
Sensitivity analysis identified a few crit-
ical model parameters. Both ofthe metabo-
lism parameters, Vam and Km. which
reflect the activity ofspecific liver enzymes
to biotransform 2,4-TDA, were found to
be the controlling parameters effecting the
excretion and accumulation of2,4-TDA
and its metabolites in each compartment.
This is consistent with the mode ofaction
of 2,4-TDA based on the literature
(10-19). A 100% increase in Vmax (or
decrease in Km), will result in a 10%
decrease in the accumulation of 2,4-TDA
in each compartment, a minimal change in
its excretion, but nearly a 50% decrease in
free plasma concentration. A 50% decrease
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in V.. (or increase in K), will also only
result in a 10% increase in accumulation in
each compartment, a minimal change in
excretion, and a large time lag in the plas-
ma concentration reduction.
In general, as D(distribution coefficient)
increases, the accumulation of2,4-TDA and
its metabolites will increase in that compart-
ment while accumulations in other com-
partments and excretions will decrease to
compensate. As expected, because the richly
perfused tissue (r) has the largest organ vol-
ume as well as the highest percentage ofthe
cardiac output, the value ofthe distribution
coefficient (Dr) also has a significant effect
on the model predictions. For example, a
100% increase in Dr will result in nearly
16% reductions in the amount of2,4-TDA
or its metabolites accumulated in the other
compartments and a minimal effect on
excretion. Similarly, a 50% decrease in Dr
will also result in nearly 8% increases in
accumulation and aminimal effect on excre-
tion. Similar changes in DL(liver),D,, (slow-
ly perfused tissue), Dk(kidney), and DGI
(GI tract) will result in very minor changes
in other compartments. These other distrib-
ution coefficients have only minor (1-2%)
effects on the tissue distributions overall;
thus, even large errors in their estimated val-
ueswill not change the overall predictions of
the model. This relative importance of Dr
sensitivity is due to a combination ofboth
organ volume and blood flow. The larger
the combination of blood flow and organ
volume to a tissue compartment, the more
impact changes in the equilibrium distribu-
tion coefficient will have on the model out-
put. The uniqueness ofthe slowly perfused
tissue response (e.g., fat tissue) compared to
other compartments is the time lag. This
compartment has the highest ratio oftissue
volume to blood flow rate; thus, changes in
the distribution coefficient in this compart-
ment manifest their effects on a slower time
scale (2-3 hr), compared to changes in other
compartments that manifest-themselves in
about 10 min.
The kidney and GI tract are unique
since they are the only compartments in
which excretion occurs. Although changes
in the distribution coefficients will have
only minor effects on excretion, the values
of Durine and Dfeces along with the flow
rates ofurine and feces, have a very signifi-
cant effect on excretion. However, solubili-
ty limitations and physiology ofthe rat put
limits on how high or how low one can
make the flow rate ofurine and feces.
Statisticalanalysis. For statistical valida-
tion (25) ofjust how well the experimental
rat results fitted the PBPK simulation
results, the log (base 10) transformed 2,4-
TDA rat blood data were shown to follow
the same linear model as the log (base 10)
transformed 2,4-TDA PBPK model predic-
tions, over the first halfhour, i.e., no statisti-
cally significant difference for either slope or
intercept between the transformed data and
the transformed predictions, even at the
10% significance level. For the 4-AAT, the
residuals ordifferences between the log (base
10) transformed 4-AAT rat blood data and
the log (base 10) transformed 4-AAT PBPK
model predictions from 0.05 to 0.5 hr were
shown to have a zero mean, no statistically
significant difference from zero even at the
40% significance level, and a 90% tolerance
interval with 90% coverage for individual
residuals of43% and 202% for the rat data
as percent ofmodel prediction.
Discussion
In the safety evaluation ofthe PU foam-cov-
ered breast implants, it is difficult to assess
the carcinogenic potential of the Meme
breast implants relative to 2,4-TDA, a muta-
gen and carcinogen known to be released
from the device (20-24). The data available
for this purpose are generally high-dose feed-
ing (4.7-10.6 mg/kg) animal data
(14-16,18,151). Therefore, we need pharma-
cokinetic models that relyon realisticphysio-
logical parameters and chemical-specific
parameters to be able to extrapolate between
high and low doses, different routes of
administration, and from animal to human
(25). The objective ofthis paper is to use the
PBPK model for 2,4-TDA in rats to predict
the long-term distribution, excretion, and
metabolism of the low-dose infusion cases
that are characteristic in humans with breast
implant degradation. The PBPK model for
2,4-TDA adequately simulated the experi-
mental 2,4-TDAand 4-AAT rat plasma data
(Fig. 2). The fit of the experimental rat
results to the PBPK model simulation results
was validated statistically as shown earlier
(25). Table 2 shows the pharmacokinetic
data of 2,4-TDA between three simulated
routes ofexposure in rats. The data obtained
from the mass balance studies shed light on
how the implant route produces a large vol-
ume of distribution (1Vd = Dose/Cmax =
54,900 ml/kg). Such a large Vdreflects high
tissue uptake and accumulation ofthe initial
dose offree 2,4-TDA and metabolites in tar-
get tissues such as the liver, kidney, and fat
(Table 2). As shown, the simulated data
obtained in this study agree well with the
distribution studies using radiolabeled 2,4-
TDA in animals, which indicated the highest
accumulation of2,4-TDA and metabolite in
the richlyperfused tissue, slowlyperfused tis-
sue, GI tract, kidney, and liver (11-13,16).
The model also predicts a slow excretion
of2,4-TDA from an implant (5% excreted in
urine in the first week and 0.94% excretion
in the feces) compared to an iv bolus and
oral administration at a given dose, confirm-
ing the experimental results obtained follow-
ing implantation with "4C 2,4-TDA-
labeled-foam (80 mg/kg) in which approxi-
mately 2% of the total radioactivity was
excreted after 56 days (29). As shown in
Table 2, the PBPK model predicts that the
continuous low-dose infusion of 2,4-TDA
produced by PU foam hydrolysis from
breast implants produces a very small AUC
(2 x 104 ng/hr/ml). The very small AUC is
due to both a slow rate ofdegradation ofthe
implant, which is assumed in this model to
be similar to the rate obtained in vitro (88
ng 2,4-TDA/g of foam per day under mild
simulated physiological conditions) (5,6). In
addition, most 2,4-TDA produced from the
breakdown of the PU foam cover is exten-
sively bound to plasma protein (9.7% free).
The plasma protein binding of 2,4-TDA
was obtained experimentally in the rat iv
study (90.3% bound).
The model-predicted results in this study
confirmed that carcinogenic degradation
products that are produced from implanted
PU foam are stored in target organs and
small amounts are excreted in animals and
humans (2,20-24,251). Although there is no
data available at this time to show a cause
and effect relationship between the use of
this PU foam and production of cancer in
humans, the lifetime duration ofexposure of
the device, the high tissue uptake, and slow
dearance of 2,4-TDA from breast implants
are important factors contributing to the
potential hazard of 2,4-TDA released from
the PU foam-covered breast implants in
humans (30). Indeed, in distribution studies,
the levels in every organ tested at 24 hr was
reported to be higher in the rat than in the
mouse, indicating more toxicity with slower
dearance and larger distribution in rats; this
is consistent with the higher cancer rate in
rats than in mice (11-13).
At a given low dose, the iv bolus and the
oral administration have about the same
clearance and equivalent AUC as shown in
Table 2. In the oral administration, howev-
er, a sustained level of2,4-TDA or metabo-
lite was found in the plasma and tissues,
indicating longer residence time (longer tl12)
and larger tissue distribution (Vd-=12,570
ml/kg) than the iv bolus administration
(16). 2,4-TDA persists longer in the body
following oral administration ofa small dose
(0.5 mg/kg), confirming the results obtained
by Timchalk et al. (16). Therefore, the
model-predicted data confirm earlier find-
ings that suggest the susceptibility to car-
cinogenic effects of2,4-TDA is also depen-
dent on the route of administration that
affects 2,4-TDA kinetic behavior and thus
the dose to target organs (16).
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As shown in Figure 4, the predicted
steady state plasma concentration W,,) of
free 2,4-TDA in the rat is very low (only
3.4 x 10-5 ng/ml), too low to be detected
by the current state of the art analytical
instrumentation (detection limits <0.1
ng/ml). However, the pharmacokinetic
data derived from this PBPK model can be
used to determine the total daily dose and
to estimate exposure. The standard phar-
macokinetic equation that relates infusion
rate, steady state plasma concentration, and
dearance ofa chemical is as follows:
Infusion rate R= C. x Clearance.
This equation predicts the rate ofrelease offree
2,4-TDA from the implants in vivoby assum-
ing that the release rate is equivalent to a con-
stantslowinfusion.Therefore, intheratmodel,
Release Rate = C x Clearance
= 3.4 x 10-5 ng/ml x 9,320 ml/hr/kg
= 0.317 ng/hr/kg
= 0.317 x 24 hr/day/1,000,000 ng/mg
= 7.60 x 10- mg/kg/day.
As such, the PBPKmodelprovides aquanti-
tative estimate ofexposure that relates both
plasmasteadystatelevelanddearance rate.
Estimated human health risksfrom
breast implants. Essentially, to estimate
human risks, we have to derive the human
exposure from the release rate of2,4-TDA
from the breast implants using the results of
the human PBPK simulation shown in
Table 2. Aswith the rat, the dearance is cal-
culated using the model by dividing the
AUC by the total administered dose (30).
The model predicts that the C. ofplasma
free 2,4-TDA is 1.55 x 10-4 ng/ml (9.7%
free) in a patient with 4.87 g PU foam in
the Meme breast implants and a body
weight of58 kg. This corresponds to aplas-
ma level of 16 x 10-4 ng/ml of total 2,4-
TDA (free + conjugated). Thus, the release
rateof2,4 TDAfromthe foam is as follows:
Release Rate = 16 x 10-4 ng/ml
x 2,175 ml/hr/kg
= 3.48 ng/kg/hr
= 3.48 x 24 hr/day/1,000,000 ng/mg
= 83.52 x 10- mg/kg/day.
This corresponds to a lifetime average daily
dose (LADD) of 11.93 x 10- mg/kg/day,
assuming that the lifetime of the implant
was 10 years (10/70). Therefore,
Upper Confidence Limit on Risk
= Potency Factor x LADD
= 0.21 (mg/kg/day)Y1 x 11.93 x 10-6
= 2.50x 10-6
= 1 in 400,000.
A potency factor (or slope factor) of 0.21
(mglkg/day)-1 was used for 2,4-TDA (23),
which results in an estimated excess cancer
riskof1 case in 400,000.
After 2,4-TDA was found as a degrada-
tion product of the meme breast implants
(2-9), a risk assessment was completed
(23,24). A small increase in lifetime risk of
breast cancer (5 in 10 million) was reported,
based on a limited in vitro rate ofrelease of
2,4 TDA (23,24). Recently, based on the
measured levels ofTDAs in the blood of
patients with the Meme PU-covered breast
implants, Sepai et al. (22) estimated an
increased riskoflifetime breast cancerof149
cases in 1 million, which is approximately60
times more than the value we obtained in
this report using a PBPK model. We believe
that the discrepancy comes from Sepai et al.
(22) calculating the risk using the postim-
plant plasma levels of total 2,4-TDA (4.4
ng/ml) obtained in patients with the Meme
breastimplants; theselevelswere 1,000 times
higher than the C. plasma level of2,4-TDA
obtained in this model. Simplyby increasing
the rate ofthe in vitro degradation that we
used in our simulations by a factor of1,000,
we were able to reproduce the C. reported
by Sepai et al. (22). No other changes in
parameters are needed. As indicated earlier,
to model the release of2,4-TDA in the rat
andhuman, we used thelowrate ofdegrada-
tion ofthe PU foam obtained in vitro using
phosphate buffered saline, pH 7.4, at 37°C
(88 ng/glday) in our calculation. The higher
plasma levels oftotal TDA that Sepai et al.
(22) obtained in patients indicate that the
PU foam degrades faster in vivo (2-4).
Although the susceptibilities ofthe PU foam
to water, buffer, oxygen, and enzymes at
physiological conditions are known (2-9),
the actual leach rate of2,4-TDA in vivo is
not well documented. Another factor that
would affect the bioavailabiity of2,4-TDA
is plasma protein binding, which was lower
in the clinical study reported by Sepai et al.
(22). Thus, PBPK models are limited by
available biochemical data such as leaching
rate and protein binding, etc; however, they
are effective tools for evaluating the safety of
2,4-TDAreleasedfromimplants.
In general, the riskassessment process has
often relied on anumber ofassumptions that
make it imprecise in determining the level of
exposure of toxic chemicals (at acceptable
risks) to the human population. In this
aspect, the PBPK model, which used both
physiological parameters (such as organ vol-
umes, bloodflows, etc.) andchemical-specific
parameters (such as tissue distribution coeffi-
cients and biotransformation rates), can be
used to predict the kinetics ofchemicals and
exrapolate between different routes ofconm-
poundadministration andspecies.
Conclusions
Despite the extreme complexity of the rat,
a relatively simple five-compartment PBPK
model gives some useful information about
the mechanism of toxicity and the route-
dependent metabolism of2,4-TDA.
* The model provides an objective mecha-
nism for determining the bioavailable
dose of the parent compound and/or its
active carcinogenic metabolite(s) at target
organs, which are inaccessible experi-
mentally.
* The plasma level offree 2,4-TDA should
not be used as a biological marker for
polyurethane foam degradation because of
its extensiveprotein binding.
* The low release rate of 2,4-TDA from
implantfoam degradationwill producethe
characteristic distribution and excretion
similar to a low dose (0.5 mg/kg) iv bolus
orfeeding, butwith alongerhalf-life and a
larger volume ofdistribution, which indi-
cateshigheraccumulation in thebody.
* Although the model has several adjustable
parameters, the only really important
parameters are the metabolism rate con-
stants Vmax and Km and the distribution
coefficient in the richly perfused tissues.
Other parameters such as the equilibrium
distribution coefficients in other compart-
ments did notaffect the 2,4-TDAdisposi-
tion significantly. Physiological limits put
restraints on many other parameters to
keep themodelpredictions realistic.
* Bydetermining Vm. andK, as rate limit-
ing steps in the biotransformation of2,4-
TDA, the PBPK model facilitates the
extrapolation across species and from one
route to another.
The PBPK results for humans can be
used to predict an excess lifetime risk of
breast and liver cancer of 1 in 400,000 in
patients with the PU foam-covered breast
implants. At our present stage, the risk asso-
ciated with exposure to a chemical cannot
be accurately characterized by a single num-
ber or even a range ofnumbers. The use of
this type ofPBPK method will provide the
Food and DrugAdministration (FDA) with
tools for the interpretation ofdata within a
single species, for comparison ofpharmaco-
kinetic result and effects between different
species, and to improve the prediction of
human effects ofmany chemicals that are
leached or degraded at a low dose rate from
medical implants. The model is most useful
in this casewhen theplasmalevel ofthepar-
ent compound (e.g., 2,4-TDA) and/or its
main metabolite are below the limit of
detection ofcurrent analytical methods (0.1
ng/ml) due to plasma protein binding.
Further research is needed on the biochemi-
cal and physicochemical characteristics of
importance to biokineticmodeling.
Volume 106, Number 7, July 1998 * Environmental Health Perspectives 398Articles * A PBPK model for 2,4-toluenediamine
REFERENCES AND NOTES
1. Scott Paper Co. Polymer Foam Modification. US
patent858,127. 7 June 1957.
2. Picha GJ, Goldstein JA, Stohr E. Natural-Y Meme
polyurethane versus smooth silicone: analysis of the
soft-tissue interaction from 3 days to 1 year in the rat
animal model. PlastReconstrSurg 85(6):903-916(1990).
3. Smahel J.Tissue reactionsto breastimplants coated with
polyurethane. PlastReconstr Surg 61(1):80-85 (1978).
4. Melmed EP. Polyurethane implants: a 6-year review of
416 patients. PlastReconstr Surg 82(2): 285-290(1988).
5. Luu HMD, White KD. In-vitro detection of2,4- and 2,6-
TDA as degradation products of a polyesterurethane
foam. Poly Degrad Stabil 42:245-251 (1993).
6. Luu HMD, Biles J,White KD. Characterization of poly-
esterurethane degradation Products. J Appi Bio
Mater 5:1-7 (1994).
7. Amin P, Willie J, Slah K, Kydonieus A. Analysis of the
extractive and hydrolytic behavior of microthane
poly(ester-urethane) foam by high pressure liquid chro-
matography. J Biomed Mater Res27:655-666(1993).
8. Batich C, Williams J, King R. Toxic hydrolysis product
from a biodegradable foam implant. J Biomed Mater
Res 23:311-319 (1989).
9. Benoit MF. Degradation of polyurethane foams used
in the Meme breast implant. J Biomed Mater Res
27:1341-1348 (1993).
10. Glinsukon T, Benjamin T, Grantham PH,Weisburger EK,
Roller PP. Enzymic N-Acetylation of2,4-toluenediamine
by liver cytosols from various species. Xenobiotica
5(8):475-483(1975).
11. Grantham PH, Mohan L, Benjamin T, Roller PP, Miller
JR, Weisburger EK. Comparison ofthe metabolism of
2,4-toluenediamine in rats and mice. J Envron Pathol
Toxicol 3:149-166 (1979).
.......
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~.
. ...........
mplazt~ Q+A)+4 i-A~ +~~
lb ~ ~~ *:. ,( 5-
ICt~~~~~~~~iLfNtt Qg tE;'V,, , 'F;
=~~~~~~~~U '.s(1K -fR rgX
.. ,e.>-?9:'--g
, : A ; :~
-i--.:.c....b:-oJi"--4.AATd-:aIkwxn equtuoo appl' ........::- . -;. .<..--X...-:-.:-.
;> .~~~wta.''e0 ; ;l0; '
..........,....,,:.,...,..,."...,..,i..,.:.... ..: ,`-,.". .......' -1-1.1.."...'.'..'........,.:-4.i:;.",...,.... ..'.......-.'...'.......;..'. .'...'...'.-'....
.;--',.' -----.,..
...
........
... ..;. .....,...... ...'. '... .. ,-j, .g ...: ...''., ..,.' .:- .:.%.'...;-.
`... ', -----', .... '.:.-.. _. .:... .. ,..i.-'...-t. -...'. ...: ...:... .:...... :...,.' -1.." ......::. -- `...... ...:.... .1. .t. ::. 'I--`-----, ..,--, .,.., --. ... ..,., ,-- .... ..."..::..; 'I. ..,....z.:.,:. ....'.'.."..,.,-..,........"....'.'.-.'.;..'..'- ,....... ...... .,.,. -,.---
---, --....... ...., ---,-- ...,.....,. ........:.,...,.... ."..,..,..",.....'.......'.....,.,....'. .". .,'-....'-.,...-, .....'.
'. ,..",.", .; ci. ----.1,.;..... "..... .....-.-......;..,.,..""
.. C
....1', ?;,.`., ..:..... .` -....: ...-.".-'.. .l ....... .-.'... -.-:-....;' ..- ., ...I..z -:- ... .-.-.... Lt....,.... ..I.. .---.. ...... ........ -,'-.--,. -.'.i7 -. .-, ..... -----..-.. .:...... z .- '... .1..-...... -,... , .. ..._., .... ...... ........ ..' -.-'..... .,-...: ,; ... .,...,.,...,......,,...'-.. ','c:.. ..'..-." ......... :...:.:.......-: .'.".,: ', `...".I,' .'.,'.,.,..,....,.,.,."",.....,.....,..,,....,..;..'-.....-...'.- P.,.... :-...-.....-.-..--"'
,...-..'...'."....,,.,.......,.,..,.,..,...,.,!,...,...,..,..'..:..,.:.'.-.'.- -....,:..... .;.,. .,.,.,...,....",;..,.,...'.'.... .... ... ...'. .............,..,.,.,-."-.."',.,,,.,,...-,.,,..,.,.,...,.., "" .......... ...................,.,....-....,- ..1......'...,...,...,::,..'.",..-1. .:.---------- --- ,... ... .....
*------ ...':..
.:..:..: .:,. - .'-....:.'.... ` --.",:-, .. .,.......".... 'I '.. .------'.'1. ...,-- --- --, -.1'I -.. :.:..''.:. .....-
------- -- ............ -....-...' ,..,.,..,.:.i:..-'..:.. .f.' .... .............,..............:::.: ...:....'.'...:,......., ;.....''..... .;..,.,.,.......,::, .'.'.'."..'.'..'." .. -"""''..... .,..I. ..........,.,.:...,.". ....... ....I.....--
..........I......,............... ............................. ...,.................. ...........'.'-..,.......-----., ...-..--!: .'...."""".'..t'..' .::..-..........i...-......-..-.....,...,.!.,......"...."...."....,.,:......--.'......'.",.,....'...,..-...",...."...";...".-.,...,.,,..".-...'-.'.'...'....'....""....,...
.,....,...,."..,,..,.'-'-'..,.....,..".,.,.,...,".....,;.......-..,....,....,."!..,....,...' .....,..".,..,......."......,:,.......'''...,...,.....,.....,........,..,.......,....,.......,..-.- ..-.,..,.,.,.......,..j,..,.,:.l .;.:".........'...". ----, ..."...,...,..,.-.....'.....,...,...... ...... .. .;.,...,.,...;.,...".,".,1 :.;.....".'....'..,.'.X` -.....?.,:...xl........,.-.;?....',--1,:.'..",.,.,....,....,.,..,....l .:.",.,.,.,.:1..t.,...,:,. ...;....-.'-.;.,..'....'.'-.'..'.'.'..'.-.'..-'..t,'. .....1.11...
-......-'....!.".,.."..,..7.......,.,.....,..,.,.,.,.",.'.. -"---.".-..--.."-...--..'.........A.'....i..j..,..,-".' ..#..........`' .-.'-.!,...........;...
..,. .W......... ...i .' ...-..
.Ll., ...,.....1..-...j... .1"' ....... -... ...'. ':.,;. ... ..". :'. ...'..: ...---, -,' ..' ... 1tt .l.:.-. ---- .,.'-- -`. .....' .-1....,.'. 1.,...:.-.-.-....-.............-.... ----.::..:...-.,..:... ... ..:.'...-,..:....1- I- .'.:. .,,, ---- ..,... ..::.:.::....'-.;,., ... ..-ik.;:"...., .Z..4....,4.,:;.!". .' .: .-'.'' .'.j.;.... ..'.c .:.... "4'. ..,.,....,.,,,.,..,.., ;....;,-, .........- '...........'..,......,'::...'..i-,-..'5 ...!-.'..-.'....;.."..,...:. -..... -, .... --- ....;t........!.:.."..,.,......... ...:..... ...,..,....,.,....,..,..,...,..".,.....-.-......"...:....,...,.,.,..,.,......:....-.........,.....,.....,..........,..?- .:..,.:.,.........,...............,....,....,...,.,..,..,...,...:,......,..,.4........,;.........:.1..... ....,......
,.,,.....,.,.......,.......,.,.,........."...,-"",.,...,...:...,.,.,.".",..,.,...,....",....",..,"...,,.:---...-....,,...,:..,' .,..,.,,.,..,......,.,.".,.,.,.,..., ......j.................. .,..,....,."..,..,~.....,,,..,.....,".". ...." ... --`---, .":,.".,..,..,...;.",.....,.,..,.,.,."..,.,..,...,..,....."...,.,.,...,.,.'..."... ....... ............ ................J. -----, .....,,,. ... ...,,...... .. ............ !,.",.,""."","...... "--- -i.-...,.,.,..,..",...,:,..,..,.,..:",.".,.,..,',...,,.'. .'....-. i-------- ---------------- --------.-..-...-..-'..............., ....;.,...,."..,....,......,.....,.1...:..... ..., ..... .;.. .., ---,.`-----, .".., ...' -- ...... ............---', --.' '..'.-.: ....' ..,...: ...... .-; -................ 'f:' l,'..l. -.... .. 1 '- ,.,:..,. ..... ..;... ."..'."'.""....""."""''-
.....l.......................: ,.....:.,.." .. :y '.-..'-.'.......,. .. ... .:... ,.. ....:: ...--..... ... -. .... ..-:..'. .. ,..,..c.-...,...,..-...r -..--, ..:. ..-.. :. at-.'.:.......,: .,.l.-:. .., ..-'..... `.. ',.-. .- .. _. ',' ''' .:.:".,... .. ., .,....,. ...: ..,..-.-....,:... ...'-t. .. ... '11.-: .....'.......J.. ..... :. ... ..........;........., ,',1k.'.. ::. '' 'I ..i.` -,
--- ----- ., ;..i. ....... ...,.." .-".-.'....-..-.....,.,..,... "-',".".'. ', :!.:... ..'. .` -....-...-.,,..".,.,.,..: ...i,.. ... ;... .. .:. -------..,:.....,.,....!.....;..':.. ,:......;...,.,........y..,."
... .: "'1
---...1.' ..: ... ... ....... -'.....l: ,'11.
--- ,.,-, '---.. .1 .i.1..:... ..'.-.."..-."'I.." .,?: --. .-- -,':.' .-........ ..:-----------..."......'-...,..,...........'-.....,..,...-...:y-:......:.:.. .,."..-,"......"..-"--- .:...........: .'-'... `. ..` .;, .....t. ,'.'
..,......,.....,:..........,.,....,....,....,....,.,..,..,.....'.....-'.,..,..'..-....'.-,....,....'..,.:."...,.,..,.,.,...,..',...,--.".'-.'.-..'-.-...;.l.:'....,......:.;..:...'.".....'-..
..,,.,.,....,....,..,.,......,.,,.....",..,' ..,..,.i..:i:--- .. 1.. "",.,..,.,.,.",,-,111,11.111 :.,..,.,j. .,.,.., ......... ........I.,..'..' 1...,;....'.,,:::.:--,-;.-.'..4 ............." ......;...;.... -....j..".. ---.--------..-. 1...,.,..,,.-..' .'...'..,..",..m..;1..'....'...'...'.
....-.-'... .11.:". 8...L.....-......--.-.; '.-.'. -'.,.... 'It ,..1.1..' t,,. .i'..? -- -..i".' -,.----- -, ...' .- ...:,:"....;.,. ----- -... --- ;.....-- -... -."'.. ..1.1..'- -, ....,:.. .:::---,.-'- ..'..'.."..'-,.. l...4..... .: .. ---- ,'- .... ..'':. '.,......,..:.
..:...:--"-..... ..'-:. ,'-..,"'-".'.-'- .. -X .-:----,-...; ".,.,,... `,,.., '; "., .....,.........,:.-`,`.;.'.,.:....--.... .'..'..'.".' --"-...,-..'..".
---- ... .....-,.:.---- .., ..... ..: .... .i:-..-'.... .j.1- ,::.....- -, -;--, -- ....' ..I.. '. ...:.;:..:v-----...... .1.1 1. ....'..t..7-":..."' -- ,,..:::...,.,.., .....-........'.,.-'..", ..;,."":..... .,,...-... ...-.,....... f..!....-r .,.'....-,..."'....." ...........i ..;.;.,,.,......,
-w--'.......;.4,.-,..,..,.,..,.. ..I.....1.l.".. .;i. .,1.''. 1 ... ... -:` --''1k...I..' '--"'......'.'..",: '.-.....,"... ---- -1 `---` ... .... .,.r...!.:....,.. ...'..' ...,.,:,..,.,.,.,..,.,..? ...,...,.:;..'-.-...,.,!.,.,.".....,.,. ,..........-,..'.,..,.,;,......'.... .,...,.,'.',..'..-;.,...... ;..........I..
.,.,,,,.,,.,,.,,, 1........n `-, ..,'....'.-.....'-..........,.v.---.' .. :.... ...... :.....:.......:1,...I. .'.,"..'.,'..'.'.' "` --.-.'-"....,....."...,.,.........-..".-......-.--..'-.,.,.,::.-,.,..,..,..,..,:....,.;..",,."...,.,..,...."-.....,-:-... .................. ''.:!.,., ,.....:.. -', ---`:'' 6.. .- ....:. .. ...". ..... -'---.-..... .!:.. --- ....`..:... ...... -.._ ..
.:.
-'. ......._.'-- :,.'.,.-.'.'-'., z. ...'....,.-
-, ....`. ,---, -,'-''.... "'...+...' '. .',..'. -:--- i.:... l.-.'.---.:;.,.,..k..,;. .... ----, -:--:,....,..,-..........., ..:
-.. - ..- ---- ....I -. ----'----,:,..'.........,.,:,.-...., .-:.. .............-----.....' ..." ,.. -, ---, ..:.-...,... ... ..... ... ---- ... ...."... ..'i.,-...' ,:..:.::..:-.-... .... .................. `--- -'` --,' ;....,...... .:. .... ..... .:,..."...,. ...,:..;..:.. .... ---- ----- ------- ............ ., ....'.'.'..'...'...'.'.;.; .... ..' .... ........'......;,i..;'
`-'-',..-..-.'.'...".e..,...,.,.,...:......,....
.. .... ...'... ;. -''.,,:- .... .....,.,.."..,...,.t,...,.,.,....,.,..,.,...,.".,.....,' ... ,...,.,."".,.".,...,.....,..........:.,..;...,.,......,." ..':+".'...".,.."....'..1.., --, ... .. e-. ..........'..:-'-......-.:.!., ...1....,,,, .....I...I.I.....I.....I.'....."..,.'.,..:.,...,.,.............!."....".'..,...'.'...."....'.'."...."'....'.'..'."..'."...'."'..,.,;,...."......,..,.,...,.,..,...,...'.
.,,,.,,,.,.,..,,..........;......-.-...,.,.."....,..,....,..,.,.,.""...".."..,..,.,.,.,.'.'....."".....,.".,,......"........-.......~.......".",!.""..,.;,.,...,.,..." .............
.,.,...,....:..,..,.............,..'-...-.'-.'-,.".....,..,.,..,.,..,..",' """""'"'"""' ,..,,,.,,.,,,..,.. .,..,..",....,.,..",.,..".,.,.' .,....,, ...'..'.''..;.....",-'.'.-'-. .','..'-'-'...'... '.....;'.':' ....".,, "I""'.."..,.,.'.'...!...,."!,.!".,- -,---------- .... ..,..,.;.". ,'..-' .-'...'.-..' t...., ......I. ...............1 ...........-................. .,.,,.,,:... .... ..-..........!."..,..,.;..,. j"z.. '.'..... -1..,..,: .",.'..,...:.. .:.:;..",.......,...,.,,.,.,.:..". ..........-'-.i.... .-----..,:,:,-,....-,.,..::.:... ..:.............:
.. ......."...""..'.- ..1:.,.....:,;.....
.- --..-.....:..-. ', ..',-..:.k ,.,.
..--- .:..:- ---T1.
', ...'''... .. .....:....''-....::- ..:. .:...... '' `.:... .-,.: ', -', .-.-.--.-.--...:..,.-.....--....-:.:...:- ----- .-..::..- ,.. ......-.-.'.--'... ....:..' ,....'...."..,.,...--......-':' ....::.'......,.,.....".,......,..,...,..,.."....,... .,::.....:.;
.....-.....--..-..;.'- ..."..........,..,.,...'-."..'..'-.'.'.-.".'-.......".'.'-...-.-..'........:"......'-.' .....,,",...",::.. ..'''.... --,---- ..-..'.... ........... ....,.. ......,",..,....,.,'.'....-.'-...... .-,.. .:.,..,.... .,....,.,....,....,........,....."...,..;..."..".....,...,...,...,. ,.....,............ .....'...-..... .... .-...........-..'. .-.'.'.... ..t...,.::.......
--''. .---..-...; ...".,.-.-.-.'-."'v. ,-','.r:,;.' .....
','-"" ',,,.,,,,.,,, ,". ,,,,,'.
','-....'. .... ............ .-. ...:......:......."..........,........................ t..........................'..-...-,..;.....-.'-..'..',.-.........,..,.....,..,.........,-?.............,.;...........-.....:...--..-..-,-..-...t.....
....... ,,,'.......... y. .....".."'..'.....'.,'.'....I.I....".;,.,...,...1..I.;....;,; ..,..........-..........,..-...,.....,...,..,......,. ,..'-.'-'-,.', '.-,.t.".,..,.,...".... ....-,..,.'j',..,..-"",'-"-.",..,.....,.,......,....'....,......,...-.'.....-'.-...,;.,....-.;..!.....".,...:.'.......j,1.).`
'.1...,.'..'..'..'..?'.,.. .. ... ...,....:. .... .!.........-...........---.---.--....-.--...-...-..-.-.-..-...-.-...-...-............;,.',""',',""',"'-..-- .-.....................--.......-...-.--.-'-.'-...,..,..,.....-.'--..-...,...-.-
:.- ::...,;... ._ .,....:.:.....-...:.:.:1
-.--------, .:, .,.,.,... -.,.---. ....,--. -.- -........... ..:.' :...,..:... il .:.. '.-... ).. .---.: .-- -----'
,,, ,,,, ....-..- .- -..."..".7,:..,..:..,..,. .:..,.."..-:.'-..f..:7.,.,.:.,:.,.,...,.-.,....' :If.'.
..t.:.........,.........................-.........................,......-,..: ,,..,.,,...,..,......,.,. ...,..,...,-......,..........-.,..,.--..".....,...-...-.-.'.-..-.,..- 5. ........................... ...... ..:..-.... .:4.:;.... ...7.:. .....-.,.........'..... ....;.-..,......-..........--....-..; ....
.:,.,1:...,.1 -',..
,.'....'.".'.,...,,......I.,.'.".'....'.,..I ........... -- ,....,......' ....I.....z..,.,....,...:.,...,.-...'....-...
.....--.Z::. ...... .-.-.-..:.,.-
.' ,.......v..t"-...,.,..,..,.."...,-'..'..- `. ...,.'.'::"
.!.;"..,..:.,...,....,...'. .,-.:.-.'., 1-..- -,-.'...-'. ..'..;.. .... ...,
-i, '."...,..,:...,.,.,..s'....
---`......
-`"---'--
, ...,..,.. -a......;..,.. M..`,', .M.........,j..,.......,...... .....,..,
c."."..,....., ..'`.......,.,....-.--..' -Wi..: ., ...,....,..,.. .. 'M........'... ..... ...!.!...........*m ......
mif ..:="......
-.".....:.:1y...,.,..,.,..,;....,."..,....".".,-.....-. ',`.. '!'-
.'..l.'s ..... .'- -, .'.'.'.. ...1.. ... ... ...--.'. ...-,.,...:.:...":.:...,...,..,.....'-.'-,.......,...,..,."....'...-.-"....'-'...'.'-'.:.:,...-......... ..,,--.'.,.,.,! '"""`-'
...-' ..r. '....:.":."..,., .:.,.:.',.--,-.'-' .1. ......"...'.'.. .'-.....:.... ..:;..5 ...:.....I..,....'.1x-.'.-.
..
.- ..i -`.:
..:... -1.-.. .. -. ..j..-... -- V-,%...'.-.
......
..,......................'....,...'
.' -.:.,.--......,.....1.'."...' ....",;:,....",..,..-...,-'...-...:.-' .01:-.-:... ..........'-'......:.........,.: .. ....., i..... -- .......,
..-D!' '...--- '..'. .^ ...----
.
----`. ,...,.. -----'. .....,..4,...,... .....,...,.., ...,..,.,..,.....,..",...........-..,.....s....' -.'.'.'..-'.-'....j%-,,.. '.. .,..'.'...-...'..'-'..'.-.".'....-..'.:. ..................... .."....."..,..".,.......,...,....,.,......,..""..' ....v...,....,. ` '.'.. ,l,;; ...' .:.'......,.' t-. ... ..i ....'i..%'. ."\ X.. --, '.',
.'.-'.-.'."-. .,...,.,.,...."......,..,.,...,..."....."..'.,.....,.,.,0..,...,.,."...'-,.,,' .,,,,,,,,,,,,,.,.,.,..'-d.`.
---` '"-.m.......1.1.11.,......-......,:..,......"'..-.-'.'..'..'...' ....-.'.-".'-..,'-'.-.,.".,..,.,.....':....:....-..".".'.".."' ....I...'..."..,
..... .'. .4,1.'-"...-'..."..:...'.-'......-.'.:.......'-.'.:,...-';.'.'...'..'.-...--..'..'-'.'.......'-.....-..'-.'.',`..,.---,..-..,.t :......:..,..
.....,Y...,..,,....,..,...',...-...'.-'..-.'...-..-.-....,.....,..,......,..........,.,..:.....,..,........,...-- .,..,...,...,..,..,:.'-'...'-.'-......-.'.-,.....v.,..'...'.-'..."'......'."...-..'..'-"...'.'.".-.'-.-'..-..-.....-.............t. ..:.,.. ..I...'.,."........',.,.,.,.'...'...'."......'.........
,.!"..,..,."..''...'.'.-.'..-.'-.;'-'.-'.'.."-.'-..-'..,..,f'..".'....-..'....,.,..,.."....'...'.'."..!.."-".'...'.-'...-..'..." .'.-.','...,.,.,,!,..,.,., --.. ---... .... .... ...'.,..,;.,..'.'..'..'..""
..- JR.' ................, .-".-.'..'...'......-.:-..-."..'.'. ..'.'..:-
,..,..,,.''.".,.'',:.l, `.,......,,...,..... .,,----, ...,......,..,.,:,.,.-..'-t-..,.,.,.-'-..'.'..'-.".,...,!i..:.--.-..-.-,-.-."'.','-.'.....,.,.....:...,........,....,..,..:...,:....,:..."...,.,..,.."-.'.'.".'-..,'..'.'.....'....-'.....-,.-.....,...,.....',"..- ....... ..!5 .4c ..' .. .. ..
........:...i. ::""..'.., ..,...,.,.,.,... 7-...'...'.'..'-,....".;,.,.".....,".-..;
.--::;.'-.,-.---..-- -..".l.."..".'..".."'.....I .ll ."..:.,.. .....-
... ,..".
Environmental Health Perspectives * Volume 106, Number 7, July 998 399Articles * Luu et al.
.................................................. :. ............ '-,,: :, :.,. ...... ....:...
. ,: .$ ,...S ' X., W ..i.:..Wi,~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~..
....
t .. n;., ..wii0. A.+,E)G ;
:... .. .; :: :. ... .. X~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~..... ..
:'° .................................................... .;~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~. .. ..........
* S ........................... '.' ,'. . Z l.d -=~~~~~~~~~~~~~~~~~~~. ......
t~~,r2kTDA~~inun
k,,~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~. ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~4 ..~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~.... ..~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~...'.':.......'.'',
.i...........................
&mited1 *con(,U;
oi
*'-'.'W..... ....... .......... ::'X'.-
S4- \iityro~~~~~~~~~~~~~ oFMTfromtotal24-TDAmetabolites(~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~32) fZ.......
12. Waring RH, Pheasant AE. Some phenolic metabolites
of 2,4-toluenediamine in the rabbit, rat, and guinea
pig.Xenobiotica 6(4):257-262(1976).
13. Weisburger EK, Russfield AB, Homburger F,
Weisburger JH, Boger E, Van Dongen CG, Chu KC.
Testing of twenty-one environmental aromatic
amines or derivatives for long term toxicity or car-
cinogenicity. J Environ Path Toxicol 2:325-356(1978).
14. Ito N, Hiasa Y, Konishi Y, Marugami M. The develop-
ment of carcinoma in liver of rats treated with M-
toluylenediamine and the synergistic and antagonistic
effects with other chemicals. Cancer Res 29(5):
1137-1145 (1969).
15. National Cancer Institute. Bioassay of 2,4-
Diaminotoluene for Possible Carcinogenicity. NCI
Technical Report Series No.162. Bethesda,
MD:National Cancer Institute, 1979.
16. Timchalk C, Smith FA, Bartels MJ. Route-dependent
comparative metabolism of [14C1toluene 2,4-diiso-
cyanate and [14Cltoluene 2,4-diamine in Fisher 344
rats. Toxicol Appi Pharmacol 124:181-190(1994).
17. Kadlubar FF, Hammons GJ. The role of cytochrome
P-450 in the metabolism of chemical carcinogens. In:
Mammalian Cytochromes P-450, vol 11 (Guengerich
FP, ed). Boca Raton, FL:CRC Press, 1987;81-130.
18. IARC. 2,4-Diaminotoluene. In: IARC Monographs onthe
Evaluation of Carcinogenic Risk of Chemicals to Man.
Vol 16: Some Aromatic Amines and Related
Compounds-Hair Dyes, Colouring Agents and
Miscellaneous Industrial Chemicals. Lyon:International
AgencyforResearch on Cancer, 1978;83-95.
19. WHO. Diaminotoluenes. Environmental Health Criteria
No 74. Geneva:World Health Organization, 1987.
20. Chan SC, Birdsell DC, Gradee CY. Detection oftoluene-
diamines in the urine of a patient with polyurethane
covered breast implants. Clin Chem 37(5):756-758
(1991).
21. Chan SC, Birdsell DC, Gradee CY. Urinary excretion of
free toluenediamines in a patient with polyurethane-
covered breast implants. Clin Chem 37(12):2143-2145
(1991).
22. Sepai 0, Henschler D, Czech S, Eckert P, Sabbioni G.
Exposure to toluenediamines from polyurethane-cov-
ered breastimplants. Toxicol Lett77:371-378 (1995).
23. Food and Drug Administration. CDRH Toxicology Risk
Assessment Committee Report on Polyester
Polyurethane Foam Covering of Silicone Gel Filled
Breast Implants. FDA Memorandum, 22July 1991.
24. Expert Panel of the Canadian Medical Association.
Safety of polyurethane-covered breast implants. Can
Med Assoc J 145:1125-1128 (1991).
25. Krishnan K, Anderson ME. Physiologically based
pharmacokinetic modeling in toxicology. In: Principles
and Methods of Toxicology (Hayes WA, ed). 3rd ed.
NewYork: Raven Press, 1994;149-188.
26. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR,
Beliles RP. Physiological parameter values for physi-
ologically based pharmacokinetic models. Toxicol Ind
Health 13:407-484(1997).
27. Ramsey JR, Anderson ME. A physiologically based
description of the inhalation pharmacokinetics of
styrene in rats and humans. Toxicol AppI Pharmacol
73:159-175(1984).
28. Anderson ME, Clewell HJ, Gargas ML, Smith FA, Reitz
RH. Physiologically based pharmacokinetics and the
risk assessment process for methylene chloride.
Toxicol AppI Pharmacol 87:185-205(1987).
29. FDA. Discretionary Postmarket Surveillance Protocol
for the Meme and Replicon Polyester/ Polyurethane-
covered Mammary Products. DPS 920001. Rockville,
MD:Food and Drug Administration, 1992.
30. Chasseaud IF. Role oftoxicokinetics in toxicitytesting.
In: Drug Toxicokinetics (Welling P, Iglesia FA, eds, Drug
and Chemical Toxicology, Vol 9. New York:Marcel
Dekker, Inc. 1993;105-142.
THIRD INTERNATIONAL CONFERENCE ON
ENVIRONMENTAL MUTAGENS IN HUMAN POPULATIONS
NOVEMBER 29-DECEMBER 4, 1998
BANGKOK * AYuDHAYA * KHAO YAI
THAILAND
Dr. Malyn Chuiasiri * Faculty of Pharmacy, Mahidol University * Sri-Ayudhaya Road, Bangkok 10400, Thailand
Phone: (662) 644-8692 * Fax: (662) 247-4696, 247-9428 * E-mail:pymcl@mahidol.ac.th
400 Volume 106, Number 7, July 1998 * Environmental Health Perspectives